	US 12,318,417 B2
	Lactobacillus compositions and methods for prevention and treatment of microbial infection
Noah Paul Zimmerman, Chapel Hill, NC (US); and Amy Wescott, Rubicon, WI (US)
Assigned to Church & Dwight Co., Inc., Princeton, NJ (US)
Filed by Church & Dwight Co., Inc., Princeton, NJ (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,939.
Claims priority of provisional application 63/129,941, filed on Dec. 23, 2020.
Prior Publication US 2022/0193157 A1, Jun. 23, 2022
Int. Cl. A61K 35/747 (2015.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)

CPC A61K 35/747 (2013.01) [A61P 31/04 (2018.01); C12N 1/205 (2021.05); C12R 2001/225 (2021.05)]

20 Claims

1. A method of reducing amount or growth of a pathogenic microbe of the urogenital tract, the method comprising administering to a subject or a sample a composition comprising an effective amount of Lactobacillus reuteri 3613 (Lr3613) deposited under NRRL accession number B-67262 and/or Lactobacillus reuteri 3613-1 (Lr3613-1) deposited under NRRL accession number B-68035,

wherein the pathogenic microbe of the urogenital tract comprises one or more of Escherichia coli, Gardnerella vaginalis, and a Candida species,

wherein the effective amount of Lactobacillus reuteri 3613, Lactobacillus reuteri 3613-1, or a combination thereof is from 1×10⁸CFU to 1×10¹¹CFU per dose of administration, from 1×10⁶CFU/g to 1×10¹⁰CFU/g, or from 1×10⁶CFU/ml to 1×10¹⁰CFU/ml, and

wherein the effective amount of Lr3613 and/or Lr3613-1 reduces the amount of growth of one or more of Escherichia coli, Gardnerella vaginalis, and a Candida species in the subject or the sample.